Investor Relations

IR Home

Stock Chart
VNDA (Common)
ExchangeNASDAQ (US Dollar)
Price$31.05
Change (%) Stock is Up 0.23 (0.75%)
Volume602,843
Data as of 01/18/19 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
January 2019?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-2-11234
01/04/19
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
4
Formats:  HTML Adobe PDF Word
5
6789101112
13141516171819
20212223242526
27282930315152

Primary IR Contact

For members of the press or investor community who wish to obtain more information about Vanda, please contact
Jim Kelly
Executive Vice President and Chief Financial Officer
Vanda Pharmaceuticals, Inc.
(202) 734-3428

Recent News
12/20/18
FDA Accepts HETLIOZ® (tasimelteon) Supplemental New Drug Application for Review in the Treatment of Jet Lag Disorder
12/10/18
Vanda Announces Positive Pivotal Study Results for HETLIOZ® (tasimelteon) in Patients with Smith-Magenis Syndrome
12/03/18
Vanda Announces Positive Phase II Study Results for Tradipitant in Patients with Gastroparesis
More >>
Upcoming Events
There are currently no events scheduled.
More >>
Corporate Presentation
Download Documentation 2019 Vanda Corporate Presentation

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.
  
Home | About Vanda | Product Pipeline| Partnering | Investor Relations | News | Careers | Contact Us
Copyright © 2005-2019 Vanda Pharmaceuticals | Terms & Conditions | Privacy Policy